Innovation Not Forgotten Art For Device Conglomerates - Wharton Panel
This article was originally published in The Gray Sheet
Large device companies play a significant role in medical technology innovation, contrary to the somewhat widespread belief that the start-up sector is the primary driver of R&D, Boston Scientific Chairman Peter Nicholas maintained.
You may also be interested in...
The low number of first-round venture capital (VC) deals in 1999 among medical device start-ups is cause for concern, according Casey McGlynn, of the Silicon Valleuy law firm Wilson Sonsini Goodrich & Rosati.
Boston Scientific's strategy to engage emerging medical device companies in a variety of collaborative arrangements provides the company an important source of R&D as well as an attractive exit strategy for the device start-ups, according to Frank Grillo, director of new business development.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.